AbbVie's Q2 2026 consensus revenue is $16.81 billion and EPS is $3.66, with shares recently trading at $265.52 against an average analyst target of $271.38.
Investors are primarily watching the revenue trajectory of the next-generation immunology franchise, specifically Skyrizi and Rinvoq, as the company completes its structural post-Humira transition.
Skyrizi is expected to lead growth with $5.52 billion in sales, effectively cushioning the impact of continued biosimilar erosion for the legacy Humira brand. Analysts are also evaluating recent pipeline additions like the $10.1 billion Apogee Therapeutics acquisition to gauge long-term earnings durability and portfolio diversification through 2030.